Announcements Trials
Browse Landscape

Phase

Phase 2 3Phase 1/2 1

Status

Completed 8Terminated 4Active not recruiting 2

Sponsor Class

OTHER 2INDUSTRY 2

Study Type

Interventional 4

Sponsor

Cancer Type

Lymphoid 1Gynecologic 1Breast 1

Conditions

Myeloid Malignancies 1Lymphoma, Follicular 1Carcinoma, Ovarian Epithelial 1Breast Neoplasms 1

Interventions

Cyclophosphamide 222pembrolizumab 201Carboplatin 173Cisplatin 168Gemcitabine 167Paclitaxel 155Docetaxel 140Bevacizumab 138Rituximab 137Radiotherapy 137Nivolumab 126Dexamethasone 126Capecitabine 103fludarabine 102Pemetrexed 92fludarabine phosphate 91Fluorouracil 91Doxorubicin 85Oxaliplatin 79Etoposide 77Cytarabine 77Bortezomib 76Erlotinib Hydrochloride 74Leucovorin 72Filgrastim 68Lenalidomide 67Calcium Dobesilate 66Irinotecan 65atezolizumab 63Radiation 61

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

4 trials
RecentStart dateEnrollment
Terminated × Has results × cc-486 × Clear all
NCT04778410 2025-03-20

Study of Magrolimab Combinations in Participants With Myeloid Malignancies

Gilead Sciences

Phase 2 Terminated
54 enrolled 26 charts

Myeloid Malignancies

NCT04722601 2024-05-16

A Dose-Finding and Efficacy Study of Venetoclax, CC-486, and Obinutuzumab in Follicular Lymphoma

University of Chicago

Phase 1/2 Terminated
2 enrolled 7 charts
Lymphoid

Lymphoma, Follicular

NCT02900560 2022-06-10

Study of Pembrolizumab With or Without CC-486 in Patients With Platinum-resistant Ovarian Cancer

Translational Research in Oncology

Phase 2 Terminated
34 enrolled 15 charts
Gynecologic

Carcinoma, Ovarian Epithelial

NCT02374099 2018-12-14

Study to Assess the Efficacy and Safety of the Epigenetic Modifying Effects of CC-486 (Oral Azacitidine) in Combination With Fulvestrant

Celgene

Phase 2 Terminated
97 enrolled 18 charts
Breast

Breast Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡